Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.23.2
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2022
Nov. 30, 2019
Jan. 31, 2018
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized           $ 2,833 $ 6,276 $ 5,787 $ 11,743
Global Blood Therapeutics | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Initial period of research term 3 years                
Additional extension period for research term upon mutual agreement 1 year                
Upfront payment receivable $ 20,000                
Additional extension period for research term     1 year         1 year  
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses 40,000                
Research agreement additional consideration               $ 7,100  
Deferred revenue, short-term           2,200   2,200  
Estimated transaction price           56,400   56,400  
Total transaction price 60,000                
Upfront non-refundable and non-creditable payment 20,000                
Reimbursable costs 40,000                
Revenue recognized           2,800 5,700 $ 5,800 10,700
Effective date of termination               Oct. 16, 2023  
Milestone-based payment receivable $ 0                
Global Blood Therapeutics | Collaboration Agreement | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Period of extension of initial research term 2 years                
Incyte                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue, short-term           0   $ 0  
Revenue recognized           $ 0 $ 600 0 $ 1,000
Incyte | Stock Purchase Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Aggregate purchase price         $ 10,000        
Shares issued         79,302        
Share price (in dollars per share)         $ 126.1        
Premium to volume-weighted sale price of shares (as a percent)         30.00%        
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares         15 days        
Incyte | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total transaction price   $ 12,300   $ 12,800       12,800  
Upfront non-refundable and non-creditable payment               2,500  
Up-front consideration         $ 10,000        
Up-front consideration, cash         2,500        
Up-front consideration, pre-paid research funding         $ 7,500        
Prepaid research amount               7,500  
Premium paid on equity investment               2,300  
Collaboration agreement additional consideration incurred               $ 500